| Toward the discovery of novel anti‐HIV drugs. Second‐generation inhibitors of the cellular ATPase DDX3 with improved anti‐HIV activity: Synthesis, structure–activity … G Maga, F Falchi, M Radi, L Botta, G Casaluce, M Bernardini, H Irannejad, ... ChemMedChem 6 (8), 1371-1389, 2011 | 106 | 2011 |
| Discovery of the first small molecule inhibitor of human DDX3 specifically designed to target the RNA binding site: towards the next generation HIV-1 inhibitors M Radi, F Falchi, A Garbelli, A Samuele, V Bernardo, S Paolucci, ... Bioorganic & medicinal chemistry letters 22 (5), 2094-2098, 2012 | 102 | 2012 |
| Pharmacophore modeling and molecular docking led to the discovery of inhibitors of human immunodeficiency virus-1 replication targeting the human cellular aspartic acid … G Maga, F Falchi, A Garbelli, A Belfiore, M Witvrouw, F Manetti, M Botta Journal of medicinal chemistry 51 (21), 6635-6638, 2008 | 100 | 2008 |
| Discovery and SAR of 1, 3, 4-thiadiazole derivatives as potent Abl tyrosine kinase inhibitors and cytodifferentiating agents M Radi, E Crespan, G Botta, F Falchi, G Maga, F Manetti, V Corradi, ... Bioorganic & medicinal chemistry letters 18 (3), 1207-1211, 2008 | 80 | 2008 |
| Fyn kinase in brain diseases and cancer: the search for inhibitors S Schenone, C Brullo, F Musumeci, M Biava, F Falchi, M Botta Current medicinal chemistry 18 (19), 2921-2942, 2011 | 77 | 2011 |
| Structure-based design of small-molecule protein–protein interaction modulators: the story so far F Falchi, F Caporuscio, M Recanatini Future medicinal chemistry 6 (3), 343-357, 2014 | 68 | 2014 |
| Targeting the human DEAD-box polypeptide 3 (DDX3) RNA helicase as a novel strategy to inhibit viral replication A Garbelli, M Radi, F Falchi, S Beermann, S Zanoli, F Manetti, U Dietrich, ... Current medicinal chemistry 18 (20), 3015-3027, 2011 | 67 | 2011 |
| Pharmacological inhibition of the ubiquitin ligase RNF5 rescues F508del-CFTR in cystic fibrosis airway epithelia E Sondo, F Falchi, E Caci, L Ferrera, E Giacomini, E Pesce, V Tomati, ... Cell Chemical Biology 25 (7), 891-905. e8, 2018 | 64 | 2018 |
| N‐[2‐Methyl‐5‐(triazol‐1‐yl)phenyl]pyrimidin‐2‐amine as a Scaffold for the Synthesis of Inhibitors of Bcr‐Abl F Arioli, S Borrelli, F Colombo, F Falchi, I Filippi, E Crespan, A Naldini, ... ChemMedChem 6 (11), 2009-2018, 2011 | 57 | 2011 |
| Computational techniques are valuable tools for the discovery of protein–protein interaction inhibitors: the 14-3-3σ case V Corradi, M Mancini, MA Santucci, T Carlomagno, D Sanfelice, M Mori, ... Bioorganic & medicinal chemistry letters 21 (22), 6867-6871, 2011 | 53 | 2011 |
| 2-Phenoxy-1, 4-naphthoquinones: From a multitarget antitrypanosomal to a potential antitumor profile F Prati, C Bergamini, MT Molina, F Falchi, A Cavalli, M Kaiser, R Brun, ... Journal of medicinal chemistry 58 (16), 6422-6434, 2015 | 50 | 2015 |
| Identification of Hck Inhibitors As Hits for the Development of Antileukemia and Anti‐HIV Agents C Tintori, I Laurenzana, F La Rocca, F Falchi, F Carraro, A Ruiz, JA Esté, ... ChemMedChem 8 (8), 1353-1360, 2013 | 50 | 2013 |
| Kernel-based, partial least squares quantitative structure-retention relationship model for UPLC retention time prediction: a useful tool for metabolite identification F Falchi, SM Bertozzi, G Ottonello, GF Ruda, G Colombano, C Fiorelli, ... Analytical chemistry 88 (19), 9510-9517, 2016 | 47 | 2016 |
| Rad51/BRCA2 disruptors inhibit homologous recombination and synergize with olaparib in pancreatic cancer cells M Roberti, F Schipani, G Bagnolini, D Milano, E Giacomini, F Falchi, ... European Journal of Medicinal Chemistry 165, 80-92, 2019 | 38 | 2019 |
| Studies on the ATP binding site of Fyn kinase for the identification of new inhibitors and their evaluation as potential agents against tauopathies and tumors C Tintori, G La Sala, G Vignaroli, L Botta, AL Fallacara, F Falchi, M Radi, ... Journal of Medicinal Chemistry 58 (11), 4590-4609, 2015 | 37 | 2015 |
| From AChE to BACE1 inhibitors: The role of the amine on the indanone scaffold A Rampa, F Mancini, A De Simone, F Falchi, F Belluti, RMC Di Martino, ... Bioorganic & Medicinal Chemistry Letters 25 (14), 2804-2808, 2015 | 34 | 2015 |
| Synthetic lethality in pancreatic cancer: Discovery of a new RAD51-BRCA2 small molecule disruptor that inhibits homologous recombination and synergizes with olaparib G Bagnolini, D Milano, M Manerba, F Schipani, JA Ortega, D Gioia, ... Journal of Medicinal Chemistry 63 (5), 2588-2619, 2020 | 33 | 2020 |
| Crassiflorone derivatives that inhibit Trypanosoma brucei glyceraldehyde-3-phosphate dehydrogenase (TbGAPDH) and Trypanosoma cruzi trypanothione reductase (TcTR) and display … E Uliassi, G Fiorani, RL Krauth-Siegel, C Bergamini, R Fato, G Bianchini, ... European Journal of Medicinal Chemistry 141, 138-148, 2017 | 32 | 2017 |
| Chalcone-based carbamates for Alzheimer’s disease treatment A Rampa, S Montanari, L Pruccoli, M Bartolini, F Falchi, A Feoli, A Cavalli, ... Future Medicinal Chemistry 9 (8), 749-764, 2017 | 32 | 2017 |
| Synthetic lethality triggered by combining olaparib with BRCA2–Rad51 disruptors F Falchi, E Giacomini, T Masini, N Boutard, L Di Ianni, M Manerba, ... ACS Chemical Biology 12 (10), 2491-2497, 2017 | 31 | 2017 |
Giovanni MagaIGM CNREmail verificata su igm.cnr.it
